Anticorps Recombinant de lapin anti-PPP2R2C

PPP2R2C Recombinant Antibody for WB, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

250997F4

N° de cat : 86383-1-PBS

Synonymes

B55 GAMMA, IMYPNO, IMYPNO1, PP2A subunit B isoform B55-gamma, PP2A subunit B isoform gamma

---

Galerie de données de validation

• 

  WB analysis using 86383-1-RR (same clone as 86383-1-PBS)

  Various lysates were subjected to SDS PAGE followed by western blot with 86383-1-RR (PPP2R2C antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 86383-1-PBS in a different storage buffer formulation.

---

Informations sur le produit

86383-1-PBS cible PPP2R2C dans les applications de WB, Indirect ELISA et montre une réactivité avec des échantillons Humain, rat, souris

• Réactivité: Humain, rat, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Recombinant
• Type: Anticorps
• Immunogène: PPP2R2C Protéine recombinante Ag3470
• Nom complet: protein phosphatase 2 (formerly 2A), regulatory subunit B, gamma isoform
• Masse moléculaire calculée: 430 aa, 49 kDa
• Poids moléculaire observé: 49-53 kDa
• Numéro d’acquisition GenBank: BC032954
• Symbole du gène: PPP2R2C
• Identification du gène (NCBI): 5522
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par protéine A
• Tampon de stockage: PBS only
• Conditions de stockage: Store at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

Protein phosphatase 2 regulatory subunit B gamma, also known as PPP2R2C or B55-gamma, encodes a gamma isoform of the subunit B55 subfamily, which is a regulatory subunit of Protein phosphatase type 2A (PP2A) (PMID: 24126060). PPP2R2C has been identified as a potential tumor suppressor in several cancers, including prostate and brain cancers (PMID: 23493267, PMID: 24126060). The decreased expression of PPP2R2C is associated with tumor progression, metastasis, and poorer patient outcomes in prostate cancer.

{{ptg:RelatedPrimaryAntibodies}}